Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis - Younossi, Zobair M.; Stepanova, Maria; Racila, Andrei; Henry, Linda; Labriola, Dominic; Taub, Rebecca; Nader, Fatema (Hepatology (Baltimore, Md.), 2025)
Keywords: Adult; Double-Blind Method; Female; Humans; Liver - pathology; Liver Cirrhosis - drug therapy; Liver Cirrhosis - etiology; Liver Cirrhosis - pathology; Male; Middle Aged; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - pathology; Quality of Life; Treatment Outcome